Anastrozole with Letrozole Improves Survival in Breast Cancer

Share this content:

the Cancer Therapy Advisor take:

Researchers who studied noninferiority of anastrozole compared with anastrozole followed by letrozole found that patients with breast cancer who received anastrozole with letrozole had better overall survival compared with patients who received anastrozole alone.

To continue their research on this topic, a new study was created to prove that treatment with anastrozole and letrozole was also superior to letrozole alone in the treatment of patients with breast cancer.

The researchers used medical records of patients who received letrozole with or without anastrozole between 2004 and 2013. The researchers then separated the patients into two groups: patients who only received letrozole and patients who received anastrozole and letrozole but then were changed to letrozole because of their reimbursement policy.

The researchers identified 359 patients who matched the specifications of the study: 179 patients where in the letrozole group and 180 patients in the anastrozole and letrozole group. In the letrozole group, patients had a mean age of 53.7. The mean age in the anastrozole and letrozole group was 54.2.

When comparing the distribution of clinical stages between the letrozole group and the anastrozole group there was 21 versus 4 patients with stage 1 disease, 86 versus 116 patients with stage 2 disease, 55 versus 48 patients with stage 3 disease, and 17 versus 14 patients with stage 4 disease, respectively.

In addition, when comparing the letrozole group with the anastrozole and letrozole group, 63.7% versus 53.9% of patients took aromatase inhibitor monotherapy and 36.3% versus 46.1% had a switching strategy, respectively. 

The researchers found that overall survival in patients receiving anastrozole and letrozole was longer than patients receiving letrozole alone. The researchers concluded that anastrozole followed by letrozole was superior in terms of overall survival than single-agent letrozole.

Lenalidomide induces the ubiquitination and degradation of CSNK1A1 by the CRBN-CRL4 E3 ubquitin liga
Patients with breast cancer who received anastrozole with letrozole had better overall survival.
The authors previously studied the noninferiority of anastrozole (ANZ) versus ANZ followed by letrozole (A-LTZ) due to reimbursement policy. They found that patients with A-LTZ had better overall survival (OS) than did patients with ANZ alone.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs